Bristol Myers Squibb to purchase Karuna Therapeutics
Bristol Myers Squibb on Friday introduced it agreed to purchase biopharmaceutical firm Karuna Therapeutics for $14 billion in money, or $330 per share. Karuna’s inventory closed up greater than 47%…